Abstract:Pseudomonas aeruginosa (PA), a predominant pathogen in lung infections, poses significant challenges due to its biofilm formation, which is the primary cause of chronic and recalcitrant pulmonary infections. Bacteria within these biofilms exhibit heightened resistance to antibiotics compared to their planktonic counterparts, and their secreted toxins exacerbate lung infections. Diverging from traditional antibacterial therapy for biofilm eradication, this study introduces a novel dry powder inhalation containing muco-inert ciprofloxacin and colistin co-encapsulated liposomes (Cipro-Col-Lips) prepared using ultrasonic spray freeze drying (USFD) technique. This USFD dry powder is designed to efficiently deliver muco-inert Cipro-Col-Lips to the lungs. Once deposited, the liposomes rapidly diffuse into the airway mucus, reaching the biofilm sites. The muco-inert Cipro-Col-Lips neutralize the biofilm-secreted toxins and simultaneously trigger the release of their therapeutic payload, exerting a synergistic antibiofilm effect. Our results demonstrated that the optimal USFD liposomal dry powder formulation exhibited satisfactory in vitro aerosol performance in terms of fine particle fraction (FPF) of 44.44 ± 0.78 %, mass median aerodynamic diameter (MMAD) of 4.27 ± 0.21 μm, and emitted dose (ED) of 99.31 ± 3.31 %. The muco-inert Cipro-Col-Lips effectively penetrate the airway mucus and accumulate at the biofilm site, neutralizing toxins and safeguarding lung cells. The triggered release of ciprofloxacin and colistin works synergistically to reduce the biofilm's antibiotic resistance, impede the development of antibiotic resistance, and eliminate 99.99 % of biofilm-embedded bacteria, including persister bacteria. Using a PA-beads induced biofilm-associated lung infection mouse model, the in vivo efficacy of this liposomal dry powder aerosol was tested, and the results demonstrated that this liposomal dry powder aerosol achieved a 99.7 % reduction in bacterial colonization, and significantly mitigated inflammation and pulmonary fibrosis. The USFD dry powder inhalation containing muco-inert Cipro-Col-Lips emerges as a promising therapeutic strategy for treating PA biofilm-associated lung infections.

Fumaryl Diketopiperazine Based Effervescent Microparticles to Escape Macrophage Phagocytosis for Enhanced Treatment of Pneumonia Via Pulmonary Delivery

Azithromycin-loaded respirable microparticles for targeted pulmonary delivery for the treatment of pneumonia

Inhalable mucin-permeable nanomicelles deliver antibiotics for effective treatment of chronic pneumonia

Formulation Optimization and in Vitro Antibacterial Ability Investigation of Azithromycin Loaded FDKP Microspheres Dry Powder Inhalation

Inhalable Polymeric Microparticles for Phage and Photothermal Synergistic Therapy of Methicillin-Resistant Staphylococcus aureus Pneumonia

Dry Powder Inhaler Formulation of High-Payload Antibiotic Nanoparticle Complex Intended for Bronchiectasis Therapy: Spray Drying versus Spray Freeze Drying Preparation.

Size-tailored and acid-degradable polyvinyl alcohol microgels for inhalation therapy of bacterial pneumonia

Polymyxin B Sulfate Inhalable Microparticles with High-Lectin-affinity Sugar Carriers for Efficient Treatment of Biofilm-Associated Pulmonary Infections.

Excipient-Free Inhalable Microparticles of Azithromycin Produced by Electrospray: A Novel Approach to Direct Pulmonary Delivery of Antibiotics

Muco-adhesive Chitosan-Coated Polyphenol Nanoparticle for Treatment of Infectious Acute Pneumonia Through Sustained Pulmonary Delivery of Polymyxin B

Dry powder inhalation containing muco-inert ciprofloxacin and colistin co-loaded liposomes for pulmonary P. Aeruginosa biofilm eradication

Polymerized cyclodextrin microparticles for sustained antibiotic delivery in lung infections

Development and characterization of a spray-dried inhalable ternary combination for the treatment of Pseudomonas aeruginosa biofilm infection in cystic fibrosis.

Inhalable tobramycin EEG powder formulation for treating Pseudomonas aeruginosa-induced lung infection

Inflammation-targeted nanoparticle with bacteria forced release of polymyxin B for pneumonia therapy

Development of a dry powder formulation for pulmonary delivery of azithromycin-loaded nanoparticles

Microenvironment responsive charge-switchable nanoparticles act on biofilm eradication and virulence inhibition for chronic lung infection treatment

An inhalable nanoparticle enabling virulence factor elimination and antibiotics delivery for pneumococcal pneumonia therapy

Poly(sebacic acid) microparticles loaded with azithromycin as potential pulmonary drug delivery system: Physicochemical properties, antibacterial behavior, and cytocompatibility studies

Dandelion inspired microparticles with highly efficient drug delivery to deep lung

Mucus-permeable polymyxin B-hyaluronic acid/ poly (lactic-co-glycolic acid) nanoparticle platform for the nebulized treatment of lung infections